Trends Shaping U. S. Pharmaceutical Industry Strategies

Trends Shaping U. S. Pharmaceutical Industry Strategies
Author: Edmund Valentine
Publisher:
Total Pages: 240
Release: 2012-07-02
Genre:
ISBN: 9780984047826

Innovate and prosper, stagnate and perish. The 13th Edition of Trends Shaping U.S. Pharmaceutical Industry Strategiesreport is designed to challenge senior management thinking and strategic assumptions - to force the hard questions that make the difference between status quo strategies that doom companies and proactive strategies that leverage resources to create increasing shareholder returns. The "Trends" report is designed to challenge conventional thinking, fight "Group Think", inject fresh/different ways of looking at pharmaceuticals...and to question product development, marketing, business development, and company strategies. It is an effective tool for the orientation of senior management employees new to the pharmaceuticals industry and serves as an excellent reference source for presentations and issues discussions.& ; & ; & ;The 13th Edition of the Trends Shaping U.S. Pharmaceuticals Industry Strategies report provides insights how the transformation of the respective United States healthcare industry market segments/stakeholders will redefine how drugs are identified, developed, reimbursed, launched, marketed, prescribed, dispensed, and taken by patients. The period to 2020 presents opportunities for companies to redefine industry norms in select therapeutic and/or product categories to create a competitive advantage.& ; & ;U.S. Pharmaceuticals represents an industry undergoing redefinition and revitalization. The 2012 to 2020 period will be typified by industry discontinuities, innovation and change. What worked in the past will not work in the future. Pharmaceutical industry norms in 2020 will be radically different than they were at the end of 2011.& ; & ;Objective, fact-based strategic planning will be the difference between success and failure for most pharmaceutical, biotechnology and generics drug companies. Strategically managed companies will anticipate and capitalize on industry change, innovate and prosper; the remainder will be broken up, acquired, merged or driven out of business. The 13th Edition of the Trends Shaping U.S. Pharmaceuticals Industry Strategies report is designed to challenge internal assumptions and corporate strategies to assist management in refining strategies to better position the company to capitalize on industry change.

Innovation and Marketing in the Pharmaceutical Industry

Innovation and Marketing in the Pharmaceutical Industry
Author: Min Ding
Publisher: Springer Science & Business Media
Total Pages: 763
Release: 2013-10-31
Genre: Medical
ISBN: 1461478014

The pharmaceutical industry is one of today’s most dynamic and complex industries, involving commercialization of cutting-edge scientific research, a huge web of stakeholders (from investors to doctors), multi-stage supply chains, fierce competition in the race to market, and a challenging regulatory environment. The stakes are high, with each new product raising the prospect of spectacular success—or failure. Worldwide revenues are approaching $1 trillion; in the U.S. alone, marketing for pharmaceutical products is, itself, a multi-billion dollar industry. In this volume, the editors showcase contributions from experts around the world to capture the state of the art in research, analysis, and practice, and covering the full spectrum of topics relating to innovation and marketing, including R&D, promotion, pricing, branding, competitive strategy, and portfolio management. Chapters include such features as: · An extensive literature review, including coverage of research from fields other than marketing · an overview of how practitioners have addressed the topic · introduction of relevant analytical tools, such as statistics and ethnographic studies · suggestions for further research by scholars and students The result is a comprehensive, state-of-the-art resource that will be of interest to researchers, policymakers, and practitioners, alike.

Leading Pharmaceutical Innovation

Leading Pharmaceutical Innovation
Author: Oliver Gassmann
Publisher: Springer Science & Business Media
Total Pages: 194
Release: 2008-02-19
Genre: Business & Economics
ISBN: 3540776362

Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.

Research and Development in the Pharmaceutical Industry (A CBO Study)

Research and Development in the Pharmaceutical Industry (A CBO Study)
Author: Congressional Budget Office
Publisher: Lulu.com
Total Pages: 65
Release: 2013-06-09
Genre: Science
ISBN: 1304121445

Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...

Science and Innovation

Science and Innovation
Author: Alfonso Gambardella
Publisher: Cambridge University Press
Total Pages: 236
Release: 1995-03-09
Genre: Business & Economics
ISBN: 0521451183

This book examines an increasingly important phenomenon for competitiveness and innovation in industry: namely, the growing use of scientific principles in industrial research. Industrial innovation still arises from systematic trial-and-error experiments with many designs and objects, but these experiments are now being guided by a more rational understanding of phenomena. This has important implications for market structure, firm strategies, and competition. Science and innovation focuses on the pharmaceutical industry. It discusses the changes that the notable advances in the life sciences in the 1980s have brought to the strategies of drug companies, the organization of their internal research, their relationships with scientific institutions, the division of labor between large pharmaceutical firms and small research-intensive suppliers, the productivity of drug discovery, and the productivity of R&D.

Making Medicines Affordable

Making Medicines Affordable
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
Total Pages: 235
Release: 2018-03-01
Genre: Medical
ISBN: 0309468086

Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.